Inspire V next-generation hypoglossal nerve stimulator launches — operational efficiency focus for sleep apnea market leader
Summary
Inspire Medical Systems launched the Inspire V in 2025 — the next-generation iteration of their market-leading hypoglossal nerve stimulator for obstructive sleep apnea. Inspire V focuses on operational efficiency improvements including faster implantation time, improved remote programming capabilities, and enhanced sleep sensing algorithms. 2026 commercial focus is on procedure volume growth and conversion from CPAP — with Inspire's addressable market estimated at the 50% of CPAP patients who ultimately abandon their mask therapy.
Why it matters
Inspire's market narrative has shifted from adoption to operational efficiency — the product works, the market is proven, and the focus is on scaling procedure volume. With 50% CPAP abandonment representing millions of potential patients, and Inspire V improving surgical throughput, the commercial scaling trajectory is clear. Inspire remains the benchmark for what neuromodulation commercial success looks like.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial